Explore what ACTEMRA has to offer:
Explore what ACTEMRA has to offer:
Explore what ACTEMRA has to offer:
WITH OR WITHOUT MTX, ACTEMRA GIVES YOU AN EVIDENCE-BASED OPTION TO PURSUE YOUR TREATMENT GOALS1
*Randomized, double-blind, 24-week, Phase III clinical study in MTX-naïve/-free patients (n=570) with moderately to severely active RA. The primary endpoint was ACR20 response at week 24.
†MTX dose was initiated at 7.5 mg/week and increased to a maximum dose of 20 mg/week within 8 weeks. The recommended starting dose for ACTEMRA IV is 4 mg/kg every 4 weeks followed by an increase to 8 mg/kg every 4 weeks based on clinical response.
ACTEMRA is not indicated for the treatment of MTX-naïve patients with RA. ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.
ACR=American College of Rheumatology; DMARD=disease-modifying antirheumatic drug; DMARD-IR=inadequate response to DMARDs; MTX=methotrexate.
Calculate the appropriate ACTEMRA dose for your patient’s weight.
Genentech provides patients support to help them access the ACTEMRA they are prescribed.
Request a payer coverage map for your practice or region.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
Jones G, et al. Ann Rheum Dis. 2010;69:88-96.
Jones G, et al. Ann Rheum Dis. 2010;69:88-96.
Kremer JM, et al. Arthritis Rheumatol. 2018;70(8):1200-1208.
Kremer JM, et al. Arthritis Rheumatol. 2018;70(8):1200-1208.
Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-2829.
Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-2829.
Bykerk VP, et al. Ann Rheum Dis. 2012;71:1950-1954.
Bykerk VP, et al. Ann Rheum Dis. 2012;71:1950-1954.
Dougados M, et al. Ann Rheum Dis. 2013;72:43-50.
Dougados M, et al. Ann Rheum Dis. 2013;72:43-50.
Weinblatt ME. Arthritis Care Res. 2013;65(3):362-371.
Weinblatt ME. Arthritis Care Res. 2013;65(3):362-371.
Ogata A, et al. Arthritis Care Res. 2014;66(3):344-354.
Ogata A, et al. Arthritis Care Res. 2014;66(3):344-354.
Gabay C, et al. Lancet. 2013;381:1541-1550.
Gabay C, et al. Lancet. 2013;381:1541-1550.
Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.
Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.
Burmester GR, et al. Ann Rheum Dis. 2014;73:69-74.
Burmester GR, et al. Ann Rheum Dis. 2014;73:69-74.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Genovese MC, et al. Arthritis Rheum. 2008;58(10):2968-2980.
Genovese MC, et al. Arthritis Rheum. 2008;58(10):2968-2980.
Data on file. Clinical Study Report. Genentech, Inc.
Data on file. Clinical Study Report. Genentech, Inc.
Kivitz A, et al. Arthritis Care Res. 2014;66(11):1653-1661.
Kivitz A, et al. Arthritis Care Res. 2014;66(11):1653-1661.
Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Yazici Y, et al. Ann Rheum Dis. 2012;71:198-205.
Yazici Y, et al. Ann Rheum Dis. 2012;71:198-205.
Bingham CO, et al. Ann Rheum Dis. 2014;74:818-822.
Bingham CO, et al. Ann Rheum Dis. 2014;74:818-822.
Smolen JS, et al. Lancet. 2008;371:987-997.
Smolen JS, et al. Lancet. 2008;371:987-997.
Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
McGrath H, et al. Rheumatology. 2004;43:1323-1325.
McGrath H, et al. Rheumatology. 2004;43:1323-1325.
Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
Choy E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
Choy E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
Data on file. LITHE Clinical Study Report. Genentech, Inc.
Data on file. LITHE Clinical Study Report. Genentech, Inc.
Data on file. ACTEMRA Studies Matrix. Genentech, Inc.
Data on file. ACTEMRA Studies Matrix. Genentech, Inc.
Data on file. PBRER Core Report. Genentech, Inc.
Data on file. PBRER Core Report. Genentech, Inc.
Data on file, Genentech, Inc.
Data on file, Genentech, Inc.
Genentech Analysis of Managed Markets Insight & Technology (MMIT) Data.
Genentech Analysis of Managed Markets Insight & Technology (MMIT) Data.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.